Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases. At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner.
Topas’ antigen-specific proprietary nanoparticle technology leverages the natural tolerogenic power of the liver. Topas nanoparticle conjugates (TPC) are designed for targeted delivery into the liver sinusoidal endothelial cells (LSECs), leading to antigen-specific tolerance, fast and rapid clearance from circulation and avoiding undesired systemic and immune reactions.
Mireia Gómez-Angelats, PhD
Chief Business Officer